Adenocarcinoma de cólon em paciente jovem

Mouräo, Domingos Augusto Carvalho; Vieira, Sabas Carlos; Barros, Marcos Aurélio de Lima; Oliveira, Francisco de Assis Moura.
J. bras. med ; 66(6): 208-10, jun. 1994. ilus
Artigo em Português | LILACS | ID: lil-163196

Documentos relacionados

  1. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
  2. Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics.
  3. Colorectal Adenocarcinoma in a 35-year-old Female with No Germline Mutations.
  4. GNG4, as a potential predictor of prognosis, is correlated with immune infiltrates in colon adenocarcinoma.
  5. A Prognostic Activity of Glutaredoxin 1 Protein (Grx1) in Colon Cancer.
  6. Pygo2 activates BRPF1 via Pygo2-H3K4me2/3 interaction to maintain malignant progression in colon cancer.
  7. Expression patterns and prognostic value of key regulators associated with m7G RNA modification based on all gene expression in colon adenocarcinoma.
  8. Adjuvant chemotherapy decision-making in stage II colon adenocarcinoma associated with patients' age and high-risk factors.
  9. Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma.
  10. Construction of a prognostic model based on genes associated with mitochondrial energy metabolic pathway in colon adenocarcinoma and its clinical significance.